title: Near-final height in 82 Chinese patients with congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency: a single-center study from China.
abstract: BACKGROUND
  The objective of this study was to identify variables that might interfere with reaching the near final height (NFH) in Congenital adrenal hyperplasia (CAH) due to classic 21-hydroxylase deficiency (21-OHD).
  
  
  METHODS
  A cross-sectional study of 82 (24 males and 58 females) classic (23 salt-wasting form [SW] and 59 simple-virilizing form [SV]) CAH 21-OHD patients seen in our institution between 1989 and 2015 with 10.6 (0.5~25.5) years of follow-up who reached their NFH was conducted. The variables related to NFH were explored.
  
  
  RESULTS
  NFH (153.35±8.31) cm, (-1.9±1.1) SD was significantly lower than the normal population (p<0.001). The treated patients reached a significantly higher NFH (-1.7±1.1) SD than those untreated (-2.6±1.0) SD (p<0.05). Both of early treatment and late treatment group were taller than untreated group (p<0.001, p=0.013, respectively), and early treatment group had a taller height trend than late treatment group (p=0.089). A better height outcome was observed in patients with advantage in target height, good compliance, and low hydrocortisone dose by multivariate Cox regression analysis in 62 treatment patients. NFH and hydrocortisone dose was negatively correlated (r=-0.23, p=0.078) in treated group. Patients complicated by central precocious puberty (CPP) received gonadotropin-releasing hormone analogue (GnRHa) plus letrozole had increased NFH with height SD for bone age and Ht SD improved after treatment compare to no intervention group (p=0.001, p=0.035).
  
  
  CONCLUSIONS
  Patients with classic 21-OHD have blunted final height, as compared with their target height and the population norm, not-treated even worse. Careful treatment adjustments have a favorable influence on growth. Alternative treatments, such as the use of puberty inhibitors GnRHa in addition to anti-estrogen therapy letrozole can somewhat improve NFH in children with 21-OHD complicated by CPP.
authors.forename: Lin
authors.initials: L
authors.lastname: Juan
authors.forename: Ma
authors.initials: M
authors.lastname: Huamei
authors.forename: Su
authors.initials: S
authors.lastname: Zhe
authors.forename: Li
authors.initials: L
authors.lastname: Yanhong
authors.forename: Chen
authors.initials: C
authors.lastname: Hongshan
authors.forename: Chen
authors.initials: C
authors.lastname: Qiuli
authors.forename: Zhang
authors.initials: Z
authors.lastname: Jun
authors.forename: Guo
authors.initials: G
authors.lastname: Song
authors.forename: Du
authors.initials: D
authors.lastname: Minlian
mesh_terms: D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000208:ethnology / Q000503:physiopathology / Q000628:therapy*; D001827:Body Height / Q000208:ethnology; D002648:Child; D002675:Child, Preschool; D002681:China; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000208:ethnology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006785:Hospitals, University; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010044:Outpatient Clinics, Hospital; D016016:Proportional Hazards Models; D011629:Puberty, Precocious / Q000208:ethnology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D012189:Retrospective Studies; D012720:Severity of Illness Index